XNCR · Nasdaq · CIK 0001326732

Xencor Inc

Xencor Inc’s most recent SEC filing in our snapshot is a Form SCHEDULE 13G/A filed on Oct 27, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $125.6M and net income of -$91.9M, according to its XBRL data on EDGAR. Its EDGAR record lists 25 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$125.6M
Net income, FY2025
-$91.9M
Form 4 filings on record, past 12 months
25

Company overview

Legal name (as filed)
Xencor Inc
Ticker
XNCR
SEC Central Index Key (CIK)
0001326732
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
PASADENA, CA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Accelerated filer
Position in SEC ticker list
#2021 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Xencor Inc’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$275.1MFY2021$164.6MFY2022$174.6MFY2023$110.5MFY2024$125.6MFY2025
Net income
$82.6MFY2021-$55.2MFY2022-$133.1MFY2023-$232.6MFY2024-$91.9MFY2025
XNCR annual results
ItemFY2021
ended Dec 31, 2021
FY2022
ended Dec 31, 2022
FY2023
ended Dec 31, 2023
FY2024
ended Dec 31, 2024
FY2025
ended Dec 31, 2025
Revenue$275.1M$164.6M$174.6M$110.5M$125.6M
Net income$82.6M-$55.2M-$133.1M-$232.6M-$91.9M
Diluted EPS$1.37-$0.93-$2.20-$3.58-$1.24
Total assets$838.2M$846.3M$965.1M$951.9M$875.5M
Cash and equivalents$143.5M$53.9M$53.8M$40.9M$54.1M

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

XNCR latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 25, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 5, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 26, 20268-KResults of operations; Regulation FD disclosure; Other events· period Oct 25, 2026Document · Index
Apr 27, 2026DEF 14ADefinitive proxy statement· period Apr 27, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Xencor Inc, by form type:

4 ×178-K ×7144 ×6SCHEDULE 13G/A ×310-Q ×2SCHEDULE 13G ×2ARS ×1DEFA14A ×1DEF 14A ×1
XNCR recent filings
FiledFormWhat it isOriginal
Oct 27, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Oct 26, 20268-KResults of operations; Regulation FD disclosure; Other events· period Oct 25, 2026Document · Index
Aug 5, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 5, 20268-KResults of operations· period Aug 5, 2026Document · Index
Jul 31, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jul 29, 20268-KMaterial agreement; Results of operations; Regulation FD disclosure· period Jul 29, 2026Document · Index
Jul 8, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 16, 2026Document · Index
Jul 8, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 16, 2026Document · Index
Jul 8, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 16, 2026Document · Index
Jul 8, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 16, 2026Document · Index
Jul 8, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 16, 2026Document · Index
Jul 8, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 16, 2026Document · Index
Jul 8, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 16, 2026Document · Index
Jul 8, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 16, 2026Document · Index
Jun 22, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 18, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 18, 20268-KShareholder vote results· period Jun 16, 2026Document · Index
Jun 17, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 15, 2026Document · Index
Jun 17, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 15, 2026Document · Index
Jun 17, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 15, 2026Document · Index
Jun 17, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 15, 2026Document · Index
Jun 15, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 15, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 15, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 15, 2026144Notice of proposed sale of securitiesDocument · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 6, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 6, 20268-KResults of operations· period May 6, 2026Document · Index
May 5, 20268-KRegulation FD disclosure· period May 4, 2026Document · Index
Apr 27, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 27, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 27, 2026DEF 14ADefinitive proxy statement· period Apr 27, 2026Document · Index
Apr 27, 20268-KDirector or officer change· period Apr 23, 2026Document · Index
Apr 13, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 10, 2026Document · Index
Apr 10, 2026144Notice of proposed sale of securitiesDocument · Index
Mar 30, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Mar 27, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Mar 9, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 5, 2026Document · Index
Mar 9, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 5, 2026Document · Index
Mar 9, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 5, 2026Document · Index

Insider filing activity

25 Form 4 filings appear in Xencor Inc’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in California

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001326732 and XBRL company facts. Xencor Inc on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.